Brazilian billionaire Lemann leads initiative to build COVID-19 vaccine factory

Henrietta Strickland
August 9, 2020

"We hope each development will succeed, but it is generally said that vaccine development is quite hard", Health Minister Katsunobu Kato told reporters.

The Austin Regional Clinic (ARC) is recruiting for a COVID-19 vaccine clinical trial set to begin this month.

AstraZeneca, which has been conducting overseas a final-stage clinical trial of its experimental AZD1222 vaccine, has not yet decided whether to inoculate a person once or twice if the vaccine is put into practical use.

The Moderna deal would make it possible to vaccinate 2.25 million people, because expectations are that two doses would be needed, it said. "This vaccine candidate has the potential to save lives and allow us to return to a way of life that will restore our economy, re-connect our friendships and continue activities we all enjoy".

AstraZeneca, interestingly, has also signed up with China-based Shenzhen Kangtai Biological Products to accelerate production on its novel vaccine.

Daiichi Sankyo Ltd, Daiichi Sankyo Biotech Co, Meiji Seika Pharma Co and KM Biologics Co will support supply in Japan, the company said. The pharmaceutical firm has been in talks with Russia, Brazil and others about supply deals for its potential vaccine.

There are no approved vaccines for COVID-19, the highly contagious respiratory illness caused by the coronavirus. Under the global inoculation drive, AstraZeneca has already eked out massive orders in a number of regions, pledging 300 million doses apiece to the USA and the European Union, along with 100 million doses for the United Kingdom and another hundred million to Brazil.

SAO PAULO Brazilian billionaire Jorge Lemann's foundation and other business interests will fund the building of factory to produce the COVID-19 vaccine being developed by Oxford University and pharmaceutical company AstraZeneca PLC.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER